

Canaccord Genuity Growth Conference

Investor Presentation

August 7th, 2019

Forward-Looking Statements

Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. Forward-looking statements in this presentation include, without limitation, projections for revenue, adjusted EPS and gross margin for fiscal years 2020, 2021 and 2022. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2019. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDAS (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income; adjusted earnings per share and free cash flow. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.


Trademarks

AngioDynamics, the AngioDynamics logo, BioFlo, the BioFlo logo, NanoKnife, the NanoKnife logo, VenaCureEVL, the VenaCureEVL logo, AngioVac, the AngioVac logo, Solero, the Solero logo, Uni-Fuse, the Uni-Fuse logo, OARtrac, Alatus, and ImmobiLoc are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. Endexo is a trademark and/or registered trademark of Interface Biologics. Habib is a trademark and/or registered trademark of Emcision.

Executing on Our Strategy



**Value
Creation**



Driving Future Growth

- Net cash balance of ~\$85 million plus \$125 million credit facility provides over \$150 million of available capital to deploy

Internal Investments:

- **Oncology, NanoKnife Platform**
- **Thrombus Management, AngioVac**
- Selective investments in Core and Vascular Access categories

External Investments:

- **M&A and Licensing for acquiring innovative assets**
- Opportunistic share repurchase and debt paydown

- Portfolio optimization will remain a priority; continued execution across entire product portfolio
- Sustained focus on operational excellence and appropriate balance sheet stewardship

AngioVac
Cannula and Circuit

BioFlo

NanoKnife


RADIADYNE
REDEFINING PATIENT MONITORING

Solero
Microwave Tissue Ablation System

VenaCure EVLT

Portfolio Optimization and Focus

Oncology Caregiver and Patient Journey



NanoKnife as a Platform



57K

CASES
DIAGNOSED
ANNUALLY

8%

5-YEAR
SURVIVAL
RATE



165K

CASES
DIAGNOSED
ANNUALLY

99%

5-YEAR
SURVIVAL
RATE



234K

CASES
DIAGNOSED
ANNUALLY

20%

5-YEAR
SURVIVAL
RATE



24K

CASES
DIAGNOSED
ANNUALLY

35%

5-YEAR
SURVIVAL
RATE

KEY
DRIVERS

- PMA PATHWAY
- CATEGORY B DESIGNATION


- UNDESIRABLE QUALITY OF LIFE OUTCOMES
- FOCAL THERAPY MOMENTUM
- RADIADYNE ADVANTAGES

- BIOPSY INTERVENTION
- MICROWAVE PENETRATION
- NxGEN IRE SOLUTION


- NxGEN IRE SOLUTION & COMBINED MODALITIES

MARKETS & OPPORTUNITIES: Oncology



Ablative Oncology Solutions



Radiation Therapy & Biopsy Solutions



MARKET & OPPORTUNITY: Thrombus Management



Our market presence, resources, and portfolio pipeline will enable us to increase our addressable market

Financial Metrics: FY20 through FY22

Our Future Growth: FY20 through FY22

Revenue
6% - 8% CAGR


Gross Margin
60% - 61%

Adjusted EPS
55% - 60% CAGR


Free Cash Flow
~\$50M+ by 2022

Adjusted EBITDAS
~\$60M by 2022


Revenue 3-Yr CAGR: 6 - 8%



Adjusted EPS 3-Yr CAGR: 55% - 60%



Gross Margin 3-Yr Improvement →60%+



Numbers for FY20, FY21, and FY22 represent estimates.